4D Molecular Therapeutics, Inc. (FDMT) shareholders
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/300% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.5%
58M of 72M shares
Institutional holders
158
31 new, 24 sold out
Net institutional buying
13M
In Q2 2026
Insider trades, 12 months
0 buys · 25 sales
Net sold $5.35M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 5,847,281 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 5,346,519 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 5,247,151 | 10.30% | 13G (passive) amendment | Mar 31, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 5,105,622 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 4,564,867 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (9.60%) | 4,423,435 | 9.60% | 13G (passive) amendment | Dec 31, 2024 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (7.50%) | 4,286,077 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Novo Holdings A/S | 3,650,737 | 6.40% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,062,596 | 6.60% | 13G (passive) amendment | Sep 30, 2025 |
| Bong Y Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (6.40%), VHCP Co-Investment Holdings III, LLC (6.40%) and 4 more | 2,952,371 | 6.40% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FDMT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 5,746,289 | 7.96% | $76.47M | New | 0.03% |
| Ra Capital Management, L.P. | 5,049,779 | 7.00% | $67.16M | – | 0.58% |
| BlackRock, Inc. | 4,546,059 | 6.30% | $60.46M | +400,756 | 0.00% |
| Goldman Sachs Group Inc | 4,258,668 | 5.90% | $56.64M | +53,230 | 0.00% |
| Novo Holdings A/S | 3,249,178 | 4.50% | $43.21M | −401,559 | 2.51% |
| State Street Corp | 2,911,109 | 4.03% | $38.72M | +203,234 | 0.00% |
| Bvf Inc/Il | 2,879,289 | 3.99% | $38.29M | – | 0.98% |
| T. Rowe Price Investment Management, Inc. | 2,511,887 | 3.48% | $33.41M | New | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 2,249,203 | 3.12% | $29.91M | +644,047 | 0.04% |
| Trails Edge Capital Partners, LP | 2,227,917 | 3.09% | $29.63M | +925,000 | 4.70% |
| Vanguard Capital Management LLC | 2,099,055 | 2.91% | $27.92M | −96,523 | 0.00% |
| Armistice Capital, LLC | 2,000,000 | 2.77% | $26.60M | – | 0.33% |
| Geode Capital Management, LLC | 1,128,466 | 1.56% | $15.01M | +63,121 | 0.00% |
| Bank Of America Corp /De/ | 1,120,674 | 1.55% | $14.90M | +146,501 | 0.00% |
| Evergreen Quality Fund GP, Ltd. | 951,474 | 1.32% | $12.65M | – | 0.20% |
| Parkman Healthcare Partners LLC | 948,184 | 1.31% | $12.61M | +425,607 | 1.29% |
| Dimensional Fund Advisors LP | 730,857 | 1.01% | $9.72M | +208,034 | 0.00% |
| Deutsche Bank AG\ | 710,942 | 0.98% | $9.46M | +2,898 | 0.00% |
| Citadel Advisors LLC | 687,597 | 0.95% | $9.15M | +423,501 | 0.00% |
| Renaissance Technologies LLC | 614,573 | 0.85% | $8.17M | +36,308 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 158 | 58M | 80.5% | 31 / 63 | 37 / 24 | 16M | 3M |
| Q1 2026 | 153 | 51M | 70.2% | 28 / 39 | 49 / 26 | 8M | 8M |
| Q4 2025 | 153 | 53M | 74.0% | 32 / 56 | 37 / 12 | 17M | 3M |
| Q3 2025 | 134 | 40M | 55.5% | 33 / 32 | 47 / 19 | 3M | 3M |
| Q2 2025 | 120 | 41M | 56.2% | 17 / 43 | 40 / 22 | 3M | 5M |
| Q1 2025 | 125 | 43M | 59.7% | 18 / 32 | 58 / 37 | 6M | 10M |
| Q4 2024 | 145 | 47M | 64.9% | 32 / 50 | 46 / 27 | 5M | 17M |
| Q3 2024 | 140 | 59M | 81.1% | 23 / 57 | 43 / 25 | 14M | 9M |
| Q2 2024 | 143 | 58M | 79.9% | 29 / 54 | 37 / 32 | 5M | 7M |
| Q1 2024 | 147 | 60M | 82.9% | 54 / 49 | 37 / 18 | 20M | 4M |
| Q4 2023 | 111 | 44M | 61.6% | 20 / 44 | 27 / 19 | 6M | 3M |
| Q3 2023 | 110 | 42M | 58.1% | 20 / 42 | 33 / 10 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
172 funds held FDMT in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FDMT | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,608,619 | 2.23% | $21.39M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,588,533 | 2.20% | $21.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,183,771 | 1.64% | $15.74M | 0.02% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 788,444 | 1.09% | $10.49M | 0.18% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 681,919 | 0.94% | $9.07M | 0.10% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 501,536 | 0.69% | $5.11M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 460,479 | 0.64% | $6.12M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 455,274 | 0.63% | $6.06M | 0.06% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 412,658 | 0.57% | $5.49M | 0.04% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 388,800 | 0.54% | $3.96M | 0.10% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 368,160 | 0.51% | $4.90M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 329,017 | 0.46% | $4.38M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 275,621 | 0.38% | $3.67M | 0.13% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 226,579 | 0.31% | $2.25M | 0.01% | May 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 209,243 | 0.29% | $2.13M | 0.10% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Kirn | See Remarks, Director | 1,309,153 | 1.81% | Oct 7, 2026 |
| Scott Bizily | Chief Legal Officer | 8,617 | 0.01% | Oct 20, 2026 |
| Christopher Paul Simms | See Remarks | – | – | Mar 27, 2026 |
| Ashoo Gupta | VP, Finance and Controller | 47,055 | 0.07% | Mar 24, 2026 |
| Kristian Humer | Chief Financial Officer | – | – | Dec 11, 2025 |
| Robert Young Kim | Chief Medical Officer | 1,595 | 0.00% | Mar 10, 2025 |
| Uneek Mehra | See Remarks | – | – | Mar 10, 2025 |
| Fariborz Kamal | President & COO | 4,347 | 0.01% | Mar 10, 2025 |
| Susannah Gray | Director | – | – | Jun 18, 2026 |
| John F. Milligan | Director | 100,000 | 0.14% | Jun 18, 2026 |
| Shawn Tomasello | Director | – | – | Jun 18, 2026 |
| Nancy Miller-Rich | Director | – | – | Jun 18, 2026 |
| Glenn Sblendorio | Director | – | – | Jun 18, 2026 |
| Charles Theuer | Director | 41,684 | 0.06% | Jun 18, 2026 |
| Jacob Chacko | Director | 0 | – | Jun 18, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Dec 10, 2024 |
| Rajeev M. Shah | 10% owner | – | – | Dec 10, 2024 |
| Peter Kolchinsky | 10% owner | – | – | Dec 10, 2024 |
| Ra Capital Management, L.P. | 10% owner | 4,563,211 | 6.32% | Dec 10, 2024 |
| Ii Gp Llc Bvf | – | – | – | Nov 13, 2024 |
| Partners OS Ltd. BVF | – | 1,570,857 | 2.18% | Nov 13, 2024 |
| Value Fund L. P. Biotechnology | – | – | – | Nov 13, 2024 |
| Partners L. P/Il Bvf | – | – | – | Nov 13, 2024 |
| Value Trading Fund OS LP Biotechnology | – | – | – | Nov 13, 2024 |
| Mark N. Lampert | – | – | – | Nov 13, 2024 |
| Value Fund Ii Lp Biotechnology | – | – | – | Nov 13, 2024 |
| I. Gp Llc Bvf | – | 662,970 | 0.92% | Nov 13, 2024 |
| Inc/Il Bvf | – | 3,040,970 | 4.21% | Nov 13, 2024 |
| Gp Holdings Llc Bvf | – | – | – | Nov 13, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Scott Bizily Chief Legal Officer | Oct 16, 2026 | Sale(10b5-1 plan) | −1,635 | $12.84 | $20.99K | 8,617 |
| Scott Bizily Chief Legal Officer | Oct 16, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| David Kirn See Remarks, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −272 | $13.61 | $3.70K | 709,153 |
| David Kirn See Remarks, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −58,061 | $12.92 | $750.24K | 709,425 |
| Scott Bizily Chief Legal Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,635 | $13.65 | $22.32K | 8,617 |
| Scott Bizily Chief Legal Officer | Sep 16, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| David Kirn See Remarks, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −58,333 | $13.90 | $810.83K | 767,486 |
| Scott Bizily Chief Legal Officer | Sep 1, 2026 | Option exercise | +584 | $6.49 | $3.79K | 9,201 |
| Scott Bizily Chief Legal Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −584 | $14.00 | $8.18K | 8,617 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Option exercise | +50,000 | $4.14 | $207.00K | 894,895 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −25,927 | $16.42 | $425.72K | 825,819 |
| David Kirn See Remarks, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −43,149 | $15.36 | $662.77K | 851,746 |
| Scott Bizily Chief Legal Officer | Aug 17, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| Scott Bizily Chief Legal Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −1,635 | $12.20 | $19.95K | 8,617 |
| Scott Bizily Chief Legal Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −1,635 | $12.00 | $19.62K | 8,617 |
| Scott Bizily Chief Legal Officer | Aug 13, 2026 | Option exercise | +1,635 | $4.14 | $6.77K | 10,252 |
| David Kirn See Remarks, Director | Aug 4, 2026 | Sale(10b5-1 plan) | −26,842 | $10.23 | $274.59K | 844,895 |
| David Kirn See Remarks, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −12,415 | $10.05 | $124.77K | 871,737 |
| David Kirn See Remarks, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −442 | $12.84 | $5.68K | 884,152 |
| David Kirn See Remarks, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −15,283 | $12.01 | $183.55K | 884,594 |
| David Kirn See Remarks, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −42,608 | $12.87 | $548.36K | 899,877 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −6,566 | $14.00 | $91.92K | 8,617 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Option exercise | +814 | $4.14 | $3.37K | 9,431 |
| Scott Bizily Chief Legal Officer | Jun 30, 2026 | Option exercise | +5,752 | $6.49 | $37.33K | 15,183 |
| Scott Bizily Chief Legal Officer | Jun 23, 2026 | Option exercise | +9,810 | $4.14 | $40.61K | 18,427 |
| Scott Bizily Chief Legal Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −9,810 | $12.00 | $117.72K | 8,617 |
| David Kirn See Remarks, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −114,746 | $10.47 | $1.20M | 942,485 |
| David Kirn See Remarks, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,922 | $10.02 | $19.26K | 1,057,231 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Sale | −80 | $8.61 | $689 | 47,055 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Option exercise | +221 | – | – | 47,135 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Option exercise | +865 | – | – | 47,224 |
| Ashoo Gupta VP, Finance and Controller | Mar 20, 2026 | Sale | −310 | $8.61 | $2.67K | 46,914 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Option exercise | +866 | – | – | 46,528 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Sale | −79 | $8.68 | $686 | 46,359 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Option exercise | +220 | – | – | 46,438 |
| Ashoo Gupta VP, Finance and Controller | Dec 20, 2025 | Sale | −310 | $8.68 | $2.69K | 46,218 |
| Scott Bizily Chief Legal Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −1,635 | $10.90 | $17.82K | 3,594 |
| Scott Bizily Chief Legal Officer | Dec 16, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 5,229 |
| Charles Theuer Director | Dec 12, 2025 | Option exercise | +9,333 | $1.14 | $10.64K | 41,684 |
| Scott Bizily Chief Legal Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −1,635 | $10.59 | $17.31K | 3,594 |
| Scott Bizily Chief Legal Officer | Nov 17, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 5,229 |
| Scott Bizily Chief Legal Officer | Oct 24, 2025 | Sale(10b5-1 plan) | −2,678 | $12.00 | $32.14K | 3,594 |
| Scott Bizily Chief Legal Officer | Oct 24, 2025 | Option exercise | +1,084 | $6.49 | $7.04K | 6,272 |
| Scott Bizily Chief Legal Officer | Oct 16, 2025 | Sale(10b5-1 plan) | −1,635 | $10.17 | $16.63K | 5,188 |
| Scott Bizily Chief Legal Officer | Oct 16, 2025 | Option exercise | +1,635 | $4.14 | $6.77K | 6,823 |
| Scott Bizily Chief Legal Officer | Oct 9, 2025 | Sale(10b5-1 plan) | −2,408 | $10.00 | $24.08K | 5,188 |
| Scott Bizily Chief Legal Officer | Sep 23, 2025 | Sale(10b5-1 plan) | −2,407 | $8.00 | $19.26K | 7,596 |
| Ra Capital Management, L.P. 10% owner | Dec 9, 2024 | Other | −535,000 | – | – | 4,563,211 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −2,378,000 | – | – | 662,970 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −240,000 | – | – | 87,911 |
| I. Gp Llc Bvf – | Nov 8, 2024 | Other | −3,062,000 | – | – | 830,237 |
| Scott Bizily Chief Legal Officer | Sep 16, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Sep 16, 2024 | Sale(10b5-1 plan) | −500 | $16.33 | $8.17K | 6,781 |
| Scott Bizily Chief Legal Officer | Aug 19, 2024 | Sale(10b5-1 plan) | −500 | $15.00 | $7.50K | 6,781 |
| Scott Bizily Chief Legal Officer | Aug 19, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Option exercise | +500 | $6.49 | $3.25K | 7,281 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Option exercise | +1,250 | $8.04 | $10.05K | 8,531 |
| Scott Bizily Chief Legal Officer | Jul 16, 2024 | Sale(10b5-1 plan) | −1,750 | $27.11 | $47.44K | 6,781 |
| Scott Bizily Chief Legal Officer | Jul 11, 2024 | Option exercise | +1,996 | $15.78 | $31.50K | 8,777 |
| Scott Bizily Chief Legal Officer | Jul 11, 2024 | Sale(10b5-1 plan) | −1,996 | $25.00 | $49.90K | 6,781 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
15.42%
11M shares short
Days to cover
10.4
At 1M shares a day
Change since last report
-5.5%
From 12M shares
Short volume, 20 days
55.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of 4D Molecular Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 50,000 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Kirn Officer | Oct 5, 2026 | 58,333 | $753.66K | Oct 5, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Sep 14, 2026 | 58,333 | $802.66K | Sep 14, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Aug 19, 2026 | 69,076 | $1.16M | Aug 19, 2026 | Acquired from issuer in private transaction |
| Scott Bizily Officer | Aug 17, 2026 | 6,540 | $79.72K | Aug 17, 2026 | Exercise of Stock Options |
| Scott Bizily Officer | Aug 13, 2026 | 1,635 | $19.41K | Aug 13, 2026 | Exercise of Stock Options |
| David Kirn Officer | Aug 4, 2026 | 26,842 | $275.40K | Aug 4, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Aug 3, 2026 | 12,415 | $125.27K | Aug 3, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Jul 10, 2026 | 15,725 | $193.57K | Jul 10, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Jul 9, 2026 | 42,608 | $549.22K | Jul 9, 2026 | Acquired from issuer in private transaction |
| Scott Bizily Officer | Jun 30, 2026 | 6,566 | $84.57K | Jun 30, 2026 | Exercise of Stock Options |
| Scott Bizily Officer | Jun 23, 2026 | 9,810 | $102.22K | Jun 23, 2026 | Exercise of Stock Options |
| David Kirn Officer | Jun 22, 2026 | 114,746 | $1.20M | Jun 22, 2026 | Acquired from issuer in private transaction |
| David Kirn Officer | Jun 1, 2026 | 1,922 | $18.66K | Jun 1, 2026 | Acquired from issuer in private transaction |
| Scott Bizily Officer | Dec 16, 2025 | 1,635 | $17.90K | Dec 16, 2025 | Exercise of Stock Options |
| Scott Bizily Officer | Nov 17, 2025 | 1,635 | $17.64K | Nov 17, 2025 | Exercise of Stock Options |
See a number that looks wrong?